Our Mission
Women’s Health
Developing the first potential “curative” non-hormonal therapeutic for endometriosis to eliminate both the disease and its associated symptoms.
Oncology
Representing a new era of precision treatment, selectively accessing targets once beyond the limits of traditional therapy and turning cold tumors responsive.
Diagnostics
Pioneering first-in-class targeted, non-invasive, definitive imaging probes, including endometriosis and colon cancer.
Leading the development of novel pharmaceuticals that will transform patient lives
Our innovation
EndoCyclic Therapeutics has spent over a decade developing an innovative platform that produces cell-permeating, pH-sensitive peptides designed to act only in diseased tissue. Built for specificity, each targeted peptide is tuned for either therapy or imaging, delivering precision without hormones, radiation, cargo agents or systemic toxicity.
Our pipeline
Our investigational products span both therapeutics and diagnostics designed to redefine care in endometriosis and oncology. ENDO-205 is a non-hormonal, disease-modifying therapeutic in development for endometriosis. FemLUNA is an investigational imaging agent being developed for precise, non-invasive diagnosis of endometriosis. We are also advancing products in oncology with additional investigational peptides, including ENDO-995, a therapeutic designed to address over 25% of malignant solid tumors, and ENDO-311, an imaging diagnostic for colorectal cancer.
Why it matters
Endometriosis affects over 190 million women and remains one of the leading causes of pain and infertility. Yet most patients face years of diagnostic delays and limited treatment options. We are changing that with the first non-invasive diagnostic and a disease-modifying "curable" therapy, built to detect and treat the root cause of disease.
Featured in
